This ASX 200 healthcare stock just hit an all-time high: Is it too late to buy?
Published
The valuation of this high-performer has soared.
Full ArticlePublished
The valuation of this high-performer has soared.
Full ArticleNeuren Pharmaceuticals just dropped its 1Q FY24 report on DAYBUE sales.